Laura Morrison, MPH

Risk of Subsequent Relapses and Corresponding Healthcare Costs Among Recently-Relapsed Medicaid Patients With Schizophrenia

BACKGROUND: Schizophrenia relapses can cause a significant increase in healthcare resource utilization and costs. However, the risk of relapse may be different between patients initiated ...

Edward S. Kim , MD, FACP, MBA;

Patrick Lefebvre , MA;

Dee Lin , PharmD, MS;

Kruti Joshi , MPH, MD;

Bruno Emond , MA;

Charmi Patel , BS , RN, BSN, MPH;

Laura Morrison , MPH;

Maria-Helene Lafeuille , MA;

11/22/2019

Real-World Outcomes Post-Transition to Once-Every-Three-Month Paliperidone Palmitate in Patients With Schizophrenia Within US Commercial and Managed Care Plans

Background: Medication non-adherence is common for patients with schizophrenia. Decreasing dosing frequency of patients adequately treated with once-monthly paliperidone palmitate (PP1M) ...

Antoine C. El Khoury , PhD;

Bruno Emond , MA;

Maryia Zhdanava , MA;

Kruti Joshi , MPH, MD;

Charmi Patel , BS , RN, BSN, MPH;

Patrick Lefebvre , MA;

Laura Morrison , MPH;

Dominic Pilon , MA;

Neeta Tandon , MA;

03/01/2019

Is Increased Severity of Major Depressive Disorder Associated With Incremental Economic Burden in Privately Insured US Patients With Treatment Resistant Depression?

Background: Among patients with major depressive disorder (MDD), those with treatment-resistant depression (TRD) have a higher economic burden. However, healthcare resource utilization (H...

Laura Morrison , MPH;

Patrick Lefebvre , MA;

John J. Sheehan , PhD, MBA, RPh;

Dominic Pilon , MA;

Kruti Joshi , MPH, MD;

Holly Szukis , MPH;

Maryia Zhdanava , MA;

03/01/2019

Real-world Comparison of Adherence Between Patients with Chronic Lymphocytic Leukemia Treated with Single-agent Ibrutinib or Acalabrutinib In First Line

Introduction:Ibrutinib and acalabrutinib are both Bruton‚Äôs tyrosine kinase inhibitors (BTKis) used to treat chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL). Since st...

Bruno Emond , MA;

Laura Morrison , MPH;

Maria-Helene Lafeuille , MA;

Xiaoxiao Lu ;

Frederic Kinkead ;

Wasiulla Khan ;

Patrick Lefebvre , MA;

Linda Wu ;

Zaina P. Qureshi ;

Ryan Jacobs ;

11/04/2022

Continuity of Care Among Patients Newly Initiated on Second-Generation Oral or Long-Acting Injectable Antipsychotics During a Schizophrenia-Related Inpatient Stay

Abstract: BACKGROUND: Quality measures were compared between patients initiated on second-generation long-acting injectable antipsychotics (SGLAIs) and oral atypical antipsychotics (OAAs)...

Charmi Patel , BS , RN, BSN, MPH;

Laura Morrison , MPH;

01/19/2023

Prevalence of Pre-existing Conditions for Adverse Events and Potential Drug-Drug Interactions Associated with Augmentation Therapies among Patients with Treatment-Resistant Depression

BACKGROUND: Comorbidities complicate clinicians' efforts to manage major depressive disorder (MDD). Pre-existing conditions and drug-drug interactions (DDI) may limit the array of safe ph...

Leslie Citrome , MD;

Laura Morrison , MPH;

John J. Sheehan , PhD, MBA, RPh;

Carmine Rossi , PhD;

Maryia Zhdanava , MA;

Oliver Lopena , PharmD;

Patrick Lefebvre , MA;

Dominic Pilon , MA;

Kruti Joshi , MPH, MD;

Swapna Karkare , MS;

10/19/2020

Cluster Analysis of Care Pathways in Major Depressive Disorder With Suicidal Ideation or Probable Suicide Attempt

BACKGROUND: To understand heterogeneity among the population with major depressive disorder (MDD) and suicidal ideation (SI) or attempt (SA) (MDD+SI/SA), clusters were identified through ...

Laura Morrison , MPH;

Maryia Zhdanava , MA;

Patrick Lefebvre , MA;

Dominic Pilon , MA;

Kruti Joshi , MPH, MD;

Cheryl Neslusan , PhD;

Tom Cornwall , PhD;

Maude Vermette-Laforme , BSc;

Abigail Nash , MD, PhD;

10/08/2020

Characteristics of Commercially Insured Patients Initiated on Esketamine Nasal Spray in a Real-World Setting

BACKGROUND: Esketamine nasal spray was approved for adults with treatment-resistant depression on 03/05/2019. Real-world data on patients initiated on esketamine is limited. METHODS: Adu...

Laura Morrison , MPH;

Swapna Karkare , MS;

Abigail Nash , MD, PhD;

Maryia Zhdanava , MA;

Aditi Shah , MA;

Patrick Lefebvre , MA;

Dominic Pilon , MA;

Kruti Joshi , MPH, MD;

10/08/2020